Palonosetron--a single-dose antiemetic adjunct for hepatic artery radioembolization: a feasibility study.
Nausea and vomiting may occur in a significant minority of patients following hepatic artery embolization with yttrium-90 spheres (K. T. Sato et al. Radiology 247:507-515, 2008). This encumbers human and economic resources and undercuts the assertion that it is as a well-tolerated outpatient treatment. A single intravenous dose of palonosetron HCl was administered before hepatic artery embolization with yttrium-90 spheres to ameliorate posttreatment nausea and vomiting, in 23 consecutive patients. The patients were discharged the day of procedure on oral antiemetics, steroids, and blockers of gastric acid release. All patients had clinical and laboratory evaluation at 2 weeks after the procedure. The data were gathered and reviewed retrospectively. At 2-week follow-up, none reported significant nausea, vomiting, additional antiemetic use, need for parenteral therapy, hospital readmission, or palonosetron-related side effects. All patients recovered from postembolization symptoms within a week after treatment. In conclusion, this retrospective study suggests that single-dose palonosetron is feasible, safe, and effective for acute and delayed nausea and vomiting in this group of patients. The added cost may be offset by benefits.
Siddiqi
Nasir H
NH
Mallinckrodt Institute of Radiology, Washington University Medical Center, St Louis, MO 63110, USA. siddiqin@mir.wustl.edu
Khan
Atif J
AJ
Devlin
Phillip M
PM
D004621:Embolization, Therapeutic / Q000379:methods*; D005240:Feasibility Studies; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000209:etiology / Q000517:prevention & control*; D000077924:Palonosetron; D011812:Quinuclidines / Q000008:administration & dosage*; D012189:Retrospective Studies; D012702:Serotonin Antagonists / Q000008:administration & dosage*; D016896:Treatment Outcome; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control*; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D007546:Isoquinolines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D015021:Yttrium Radioisotopes; D000077924:Palonosetron